PMC full text: | Published online 2018 Jan 31. doi: 10.1038/s41598-018-20471-5
|
Characteristics | Training Set (n=114) | Validation Set (n=176) | P-value (Fisher test) |
---|---|---|---|
Sex | |||
Male | 59 (52%) | 94 (53%) | 0.81 |
Female | 55 (48%) | 82 (47%) | |
Age at Treatment, yr, median (min-max) | 67 (42–84) | 68 (39–87) | 0.21* |
Karnofsky performance status | 0.11 | ||
70–100 | 107 (94%) | 173 (98%) | |
<70 | 7 (6%) | 4 (2%) | |
Tumor Histology | 0.04 | ||
Adenocarcinoma/NOS | 63 (55%) | 119 (68%) | |
Squamous | 51 (45%) | 57 (32%) | |
T Status | 0.005 | ||
T1 | 34 (30%) | 84 (48%) | |
T2 | 55 (48%) | 71 (40%) | |
T3/4 | 25 (22%) | 21 (12%) | |
N Status | 0.35 | ||
N0 | 79 (69%) | 131 (74%) | |
N1/2 | 35 (31%) | 45 (26%) | |
Smoking Status | 0.003 | ||
Never | 5 (4%) | 24 (14%) | |
Former | 52 (46%) | 93 (53%) | |
Current | 57 (50%) | 59 (34%) | |
Adjuvant Therapy | 0.002 | ||
Yes | 49 (43%) | 45 (26%) | |
No | 64 (57%) | 131 (74%) | |
Margin Status | |||
Close(<2mm)/Positive | 7 (6%) | 9 (5%) | 0.79 |
Negative | 107 (94%) | 167 (95%) |
Abbreviations: NOS, not otherwise specified.
*T-test utilized.